KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) EBIT (2017 - 2025)

Moderna (MRNA) has disclosed EBIT for 9 consecutive years, with -$857.0 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 31.22% to -$857.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.1 billion through Dec 2025, up 22.08% year-over-year, with the annual reading at -$3.1 billion for FY2025, 22.08% up from the prior year.
  • EBIT for Q4 2025 was -$857.0 million at Moderna, down from -$260.0 million in the prior quarter.
  • The five-year high for EBIT was $5.4 billion in Q4 2021, with the low at -$2.0 billion in Q3 2023.
  • Average EBIT over 5 years is $572.9 million, with a median of -$165.0 million recorded in 2024.
  • The sharpest move saw EBIT skyrocketed 2609.84% in 2021, then plummeted 20866.67% in 2024.
  • Over 5 years, EBIT stood at $5.4 billion in 2021, then crashed by 70.79% to $1.6 billion in 2022, then tumbled by 99.62% to $6.0 million in 2023, then tumbled by 20866.67% to -$1.2 billion in 2024, then soared by 31.22% to -$857.0 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$857.0 million, -$260.0 million, and -$907.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.